Epimedium for Osteoporosis and Periodontitis Treatment
Author Information
Author(s): Guo Ying, Ge Xu, Wang Wei, Wang Rongrong, Chen Qianmin, Wang Hong
Primary Institution: General Hospital of Shenzhen University
Hypothesis
Epimedium, when used as an adjunct to standard osteoporosis treatment, will enhance BMD and simultaneously reduce periodontal inflammation in patients with coexisting osteoporosis and periodontitis.
Conclusion
Epimedium shows promise as an adjunctive therapy in patients with osteoporosis and periodontitis, contributing to improved BMD, reduced inflammation, and enhanced periodontal health.
Supporting Evidence
- Patients receiving Epimedium showed significantly greater increases in lumbar spine and proximal femur BMD.
- Periodontal health metrics improved more in the observation group compared to the control group.
- The total effective rates for osteoporosis and periodontitis were higher in the observation group.
Takeaway
This study found that a herbal treatment called Epimedium can help people with weak bones and gum disease feel better and healthier.
Methodology
This retrospective study analyzed clinical data from 120 patients with osteoporosis and periodontitis, divided into two groups receiving different treatments.
Limitations
The study may lack geographical diversity and did not control for lifestyle factors that could affect outcomes.
Participant Demographics
Patients were middle-aged and elderly individuals with osteoporosis and periodontitis.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website